64 results
8-K
EX-10.1
PCSA
Processa Pharmaceuticals Inc
30 Jan 24
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
10:46am
responsibility against such losses and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries
424B4
PCSA
Processa Pharmaceuticals Inc
29 Jan 24
Prospectus supplement with pricing info
4:15pm
responsibility for, and can provide no assurance as to the reliability of, any information that others may provide to you. This prospectus is not an offer to sell … activities.
Setting Executive Compensation
Our compensation committee has primary responsibility for, among other things, determining our
8-K
EX-3.1
vaydr9ozh
21 Sep 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:29pm
8-K
EX-10.1
cxu53a vs
24 Mar 22
Entry into a Material Definitive Agreement
4:30pm
424B5
p8xhujk9z2qkbudgc
24 Mar 22
Prospectus supplement for primary offering
4:15pm
PRE 14A
8xup8b1
1 Sep 21
Preliminary proxy
4:46pm
424B5
ed72 50p41
20 Aug 21
Prospectus supplement for primary offering
4:46pm
8-K
EX-1.1
1c3361wk ami
20 Aug 21
Entry into a Material Definitive Agreement
4:30pm